Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Capital Expenditures of -$8939.0 for Q1 2026, up 38.18% year-over-year from -$6469.2 in Q1 2025, and up 81.2% quarter-over-quarter from -$47544.5 in Q4 2025.

Analysis

Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026) Analysis & Trends

Oculis Holding AG's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$8939.0 for Q1 2026.

  • In Q1 2026, Capital Expenditures rose 38.18% year-over-year to -$8939.0; the TTM figure through Mar 2026 stood at -$363691.2 (down 38.33% YoY), while the FY2025 annual figure was -$363044.7, down 38.86% from the prior year.
  • Capital Expenditures for Q1 2026 stood at -$8939.0, up from -$47544.5 in the prior quarter.
  • The five-year high for Capital Expenditures was -$5636.8 in Q4 2023, with the low at -$1.6 million in Q4 2022.
  • The 5-year median for Capital Expenditures is -$65066.7 (2024), against an average of -$251973.4.
  • The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 99.65% in 2023, then tumbled 1054.33% in 2024.
  • Oculis Holding AG's Capital Expenditures stood at -$1.6 million in 2022, then soared by 99.65% to -$5636.8 in 2023, then sank by 1054.33% to -$65066.7 in 2024, then advanced by 26.93% to -$47544.5 in 2025, then jumped by 81.2% to -$8939.0 in 2026.
  • Business Quant data shows OCS's Capital Expenditures at -$8939.0 in Q1 2026, -$47544.5 in Q4 2025, and -$155013.6 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 112.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 240.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 37.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.29 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 25.02 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 34.68 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 251.02 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 6.26 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - 354,266.95
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 354,266.95
Mar 31, 2026 247,738.91
Dec 31, 2025 517,984.29
Sep 30, 2025 -311,277.27
Jun 30, 2025 163,065.18
Mar 31, 2025 325,889.41
Dec 31, 2024 1.04 Mn
Sep 30, 2024 -707,529.04
Jun 30, 2024 471,068.03
Mar 31, 2024 16,039.55
Dec 31, 2023 485,889.78
Sep 30, 2023 -10,189.37
Dec 31, 2022 -14,532.31
Sep 30, 2022 -31,063.70